Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line

Clinical Cancer Research

Volumn 8, Issue 6, 2002, Pages 2002-2009

  Smith, Victoria ^a   Rowlands, Martin G ^a   Barrie, Elaine ^a   Workman, Paul ^a   Kelland, Lloyd R ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GGTI 298; GLYCOPROTEIN P; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB;

ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG RESISTANCE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN CELL; PHOSPHORYLATION; PRIORITY JOURNAL; TREATMENT PLANNING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL DIVISION; CHROMONES; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FARNESYLTRANSTRANSFERASE; HUMANS; MORPHOLINES; PHOSPHORYLATION; QUINAZOLINES; QUINOLONES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036284741     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Protein prenylation: Genes, enzymes, targets and functions
2. Farnesyl transferase inhibitors and cancer treatment: Targeting simply ras?
3. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
4. Farnesyl transferase inhibitors: A novel targeted therapy for cancer
5. Farnesyl transferase and geranylgeranyltransferase 1 inhibitors in cancer therapy: Important mechanistic and bench to bedside issues
6. Farnesyl transferase inhibitors alter the prenylation and growth-stimulating function of RhoB
7. Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol
8. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
9. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro
10. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyl transferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, taxol and gemcitabine
11. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines
12. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line
13. Lack of a role for MRPI in platinum drug resistance in human ovarian cancer cell lines
14. New colorimetric cytotoxicity assay for anticancer-drug screening
15. Comparison of potential markers of farnesyl transferase inhibition
16. Inhibition of protein prenylation by metabolites of limonene
17. Identification of a novel inhibitor of Mitogen-activated Protein Kinase Kinase
18. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
19. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner
20. A family of drug transporters: The multidrug resistance-associated proteins
21. P-glycoprotein - A mediator of multidrug resistance in tumour cells
22. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer
23. Isoprenylation is required for the processing of the lamin a precursor
24. Protein farnesyl transferase and geranylgeranyltransferase share a common α subunit
25. K- and N-ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
26. Amino acid substitutions that convert the protein substrate specificity of farnesyl transferase to that of geranylgeranyltransferase Type I
27. Insulin stimulates the phosphorylation and activity of farnesyl transferase via the Ras-mitogen-activated protein kinase pathway
28. Interaction of the transforming growth factor-β type I receptor with farnesyl-protein transferase-α
29. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
30. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects